Among RAD 140 side effects, the best documented is drug-induced liver injury, harm to liver tissue from a compound. RAD140 itself is an investigational compound from breast cancer research. Raised liver function tests were the commonest adverse events in the only full human trial, in women with advanced breast cancer, and published cases describe young men with jaundice.
In those cases drug-induced liver injury followed weeks to months of exposure, and most of the men recovered once exposure ended. Further case reports describe inflammation of cardiac tissue, whereas hair loss, acne, insomnia and mood changes are described only outside any trial.
RAD140 is a non-steroidal compound with tissue-selective androgenic activity, known as a selective androgen receptor modulator (SARM). The RAD 140 mechanism of action resembles that of androgens: it acts through a protein inside cells called the androgen receptor. Later trials tested RAD-140 under the development name vosilasarm, and case reports also call it testolone, the name on the product in one case of cardiac inflammation.
The evidence comes in three tiers. The first is the single full human trial, joined by a later abstract that recorded the same rises in liver function tests at a lower dose. The second is the case reports, which describe drug-induced liver injury, inflammation of cardiac tissue, and gynaecomastia, an enlargement of glandular breast tissue in males, with suppressed sex hormone levels after products that also held undeclared hormones. The third is the effects described outside any trial, drawn from RAD 140 experience reports on Reddit and in similar accounts.
Whether RAD 140 is safe or dangerous cannot be read from this record. Its documented harms are real, but they rest on a small trial and single cases, which give neither a safe dose nor a rate of harm in healthy adults. This article sets out what each tier records and leaves aside effects on skeletal muscle and legal detail beyond approval and sport.
What side effects did the human clinical trial report, and how often?
Raised liver function tests were the most frequent adverse events in the first-in-human phase 1 trial, an early safety test in humans. The two commonest were rises in the enzymes aspartate aminotransferase (AST), which injured liver cells release, and alanine aminotransferase (ALT), which is more liver-specific. The patients were heavily pretreated postmenopausal women with metastatic breast cancer positive for the oestrogen receptor, the protein in cells that responds to oestrogens. They received one of three once-daily doses; the severity table below gives the sizes and the arm numbers.
The chart shows these events, which count as treatment-emergent adverse events because they began or worsened during treatment. Among them is raised total bilirubin, a yellow pigment that liver cells clear into bile.
[Figure 1. Adverse events in RAD140’s first human trial. Treatment-emergent adverse events seen in more than 10% of 22 women with advanced breast cancer taking 50, 100 or 150 mg of RAD140 daily, doses pooled. Raised AST and ALT led the list. The rates come from seriously ill patients, not healthy adults.]
The investigators scored the events by adverse event grade, the standard scale of clinical severity on which a severe event is 3 and a life-threatening one 4. Events of grade 3 or 4 affected most patients, among them raised AST or ALT and hypophosphataemia, an abnormally low level of phosphate in the blood. Events related to treatment were slightly more common still, and the table below sets out their severity.
The trial set the maximum tolerated dose, the highest dose without unacceptable toxicity, at the middle of the three daily doses in the table. The elimination half-life, the time the blood concentration takes to halve, was 44.7 hours, which supported once-daily administration. On these data the authors judged the safety profile acceptable for patients with this cancer. Even so, a later phase 1/2 abstract of vosilasarm in the same disease recorded raised liver function tests at 10 mg twice daily. Together these figures make up most of the safety data from the RAD-140 clinical trials, and they come from a small group of older, ill and heavily pretreated patients, so the rates do not transfer neatly to healthy young men.
Was RAD140 linked to cancer in these studies?
RAD140 was not found to cause cancer in these studies, which tested it as a candidate treatment for breast tumours positive for both the androgen receptor and the oestrogen receptor (AR+/ER+). It activated the androgen receptor and slowed tumour growth in patient-derived xenografts, human tumours grown in laboratory mice, and it suppressed the oestrogen receptor pathway, including ESR1, the gene that encodes the oestrogen receptor. That activity showed tissue selectivity, a dependence on where the receptor sits: RAD140 activated it in breast cancer cells but not in prostate cancer cells, and in rats it largely spared the prostate.
In the trial itself, prostate-specific antigen (PSA), a protein produced in response to androgens, rose in 16 of 20 women, and the authors read the rise as a sign that RAD140 had reached the androgen receptor. These studies tested the compound against cancer in patients and models; none of them measured whether RAD 140 causes cancer in healthy humans.
[Figure 2. RAD140 and breast tumour growth in mice. In breast cancer cell lines and in human AR+/ER+ tumours grown in mice, RAD140 activated the androgen receptor, suppressed the oestrogen receptor pathway including ESR1, and slowed tumour growth. It did not activate the receptor in prostate cancer cells. It was not tested in people.]
Liver injury in the case reports
Case reports on RAD 140 and the liver describe drug-induced liver injury in young men after weeks to months of exposure to products labelled as supplements, and in each the injury was marked by cholestasis, an impairment of bile flow from the liver. The first report, set out with the others in the liver article, describes a young man who presented after some weeks of exposure with abdominal pain, itching, yellowing of the eyes and jaundice, a yellow discolouration caused by retained bilirubin. His injury was cholestatic, with a steep rise in total bilirubin, and a liver biopsy, a needle sample of liver tissue, showed cholestasis with minimal portal inflammation.
The published cases share a cholestatic pattern, which parallels the raised liver function tests of the phase 1 trial, as one of the reports itself points out. Other SARMs have been associated with the same pattern, so cholestasis is one of the liver effects of SARMs across the class, not of RAD140 alone.
Is RAD140 bad for the kidneys?
The evidence on RAD140 kidney effects amounts to acute kidney injury, a sudden fall in renal function, in a single published case of severe drug-induced liver injury after exposure to two compounds. That case cannot show whether RAD140 itself damages the organ.
It is the most severe drug-induced liver injury associated with RAD140 reported to date, in a previously healthy young man exposed to a supplement containing RAD140 and andarine (S4), an earlier SARM of the same class. His cholestatic injury kept progressing despite withdrawal of the supplement and treatment with corticosteroids, the steroid medicines that suppress inflammation, so he required plasmapheresis, a procedure that removes and replaces the liquid part of the blood. Pancreatitis, inflammation of the pancreas, and acute kidney injury then complicated his course further, and he required intensive care.
Heart inflammation and other serious case reports
Beyond drug-induced liver injury, case reports on RAD-140 and the heart describe inflammation of cardiac tissue, and one further report describes a splenic rupture, a tear of the spleen without preceding trauma. In the first heart case, a 16-year-old boy developed myopericarditis, inflammation of the heart muscle and the sac around it, after first exposure to a product sold as testolone; the authors call such adverse effects potentially life-threatening and poorly characterised. A separate case describes a young man who presented with possible acute myocarditis, inflammation confined to the cardiac muscle itself, after exposure to RAD140.
The splenic rupture occurred spontaneously in a 54-year-old man after recent exposure to RAD140 with MK-677 (ibutamoren), a compound that stimulates the release of growth hormone. The clinicians first blocked the bleeding splenic artery by embolisation and then removed the spleen. The removed tissue, however, showed features of a possible vascular malformation, and the authors call any role of the compounds speculative. That single case is the whole published record on RAD140 combined with MK-677, whose own record is set out under MK-677 side effects. None of these reports proves that RAD140 caused the harm, because each describes one patient.
Does RAD140 raise blood pressure or cause chest tightness?
Raised blood pressure and chest tightness are described beyond the trial data as effects RAD140 is able to cause, and in some accounts the tightness is severe enough to end exposure within the first weeks. Chest pain has also been described as an effect of RAD140, sometimes within the first days of exposure, alongside a faster heart rate, shortness of breath and palpitations, an awareness of a forceful or irregular heartbeat. Very high blood pressure is described, outside the trial record, as an occasional finding, now and then at levels regarded as dangerous. Accounts outside the published studies also describe the opposite: an uneventful course, free of any chest or cardiac symptom.
Does RAD140 cause gyno?
Only one documented case links RAD140 to gynaecomastia, an enlargement of glandular breast tissue in males, and the products in that case also held undisclosed hormones, so the enlargement cannot be attributed to RAD140 alone. That case report describes a 40-year-old man who developed bilateral gynaecomastia after 6 months of exposure to commercial supplements, together with hypogonadotropic hypogonadism, a state in which deficient pituitary or hypothalamic signalling leaves gonadal hormone output low, the same suppression that lies behind questions of RAD140 and testicle size. Laboratory analysis of those supplements found RAD-140, MK-677 and cardarine, a compound classed as performance-enhancing, together with undeclared growth hormone and two undeclared sex hormones: testosterone and oestradiol, the most potent natural oestrogen. The gynaecomastia resolved fully once exposure to the supplements ended.
In vitro analysis also detected undisclosed hormones testosterone, estradiol, and GH in all 3 supplements
Beyond that single case, the laboratory work on breast cancer offers only indirect context: in breast cancer models RAD140 activated the androgen receptor and suppressed the oestrogen receptor pathway. That work used cancer tissue in the laboratory rather than male breast tissue, so it does not show how RAD140 acts on the tissue that enlarges in gynaecomastia.
Nipple swelling and lumps described in discussions
In descriptions beyond the trials, swelling around the nipple or a small, tender lump beneath one nipple appears within the first weeks of exposure to RAD140, and in a few accounts within the first week itself. Gynaecomastia earlier in life is described, outside the trial record, as grounds for concern that the condition may recur. Accounts outside the published studies also set two further views side by side: that gynaecomastia cannot arise because RAD140 is not converted into oestrogen, and that levels of the hormone had fallen too low.
Testosterone, SHBG and other hormone changes
The sources record two hormone changes: a fall in a hormone-binding protein in the first-in-human trial, and suppressed testosterone production in one case. Sex hormone-binding globulin (SHBG), the protein that carries sex hormones in the blood, fell in all 18 women measured, and the authors took that fall as a marker of RAD140 acting on the androgen receptor. In men, testosterone production is governed by the hypothalamic-pituitary-gonadal axis, a feedback loop linking the hypothalamus, the pituitary gland and the gonads. The loop acts through luteinising hormone, the pituitary signal that drives testosterone production.
The RAD-140 hypogonadism case report records suppression of that axis: luteinising hormone and testosterone were both low, and they returned to normal together after exposure to the products ended. The products held undeclared testosterone and oestradiol as well as RAD-140, so the suppression cannot be attributed to the SARM alone, and the case cannot answer the question that remains when RAD140 acts by itself: does RAD 140 increase testosterone or lower it?
Does RAD140 cause hair loss?
In accounts outside the trials, RAD140 hair loss is the most widely described effect, in the form of shedding, thinning and a receding hairline. Such shedding begins, in those accounts, within the first days or weeks of exposure, most often where a predisposition to androgenetic alopecia, male-pattern baldness, already existed. Outside the published trials, exposure is sometimes said to have ended early because of that shedding, and RAD140 is widely described as acting strongly on scalp hair. In descriptions beyond the trials, however, an absence of any hair loss also appears.
Does RAD140 cause hair loss, and does it stop after the cycle?
RAD140 is described, outside the trial record, as causing hair shedding that starts a few weeks into exposure, eases and then stops some weeks later, whether the product was still being taken or not. The shedding has also been described as continuing after exposure ended, a course that leaves open when it stops and whether the loss is permanent. In descriptions beyond the trials, by contrast, no later shedding appears where none was seen at the start.
Does RAD140 cause acne?
Acne is described outside the trials as a possible effect of RAD140, seen as new lesions on the face and back and, in a few accounts, as red lesions on the back after exposure ended. In other instances accounts outside the published studies describe the skin as unchanged, and outside the published trials existing acne is described as clearing during exposure in a few accounts. The overall picture is mixed rather than pointing one way.
Does RAD140 cause insomnia?
Insomnia, widely set out as difficulty falling or staying asleep, early waking and a persistent shortage of rest, is described beyond the trial data as an effect RAD140 is able to cause. Accounts outside the published studies describe that disturbed sleep as accompanied by night sweats, a sensation of heat at night and nightmares. Outside the published trials, the time of day of exposure is sometimes described as a possible influence, a possibility that rests on description alone. Normal nights have also been described in other accounts, so the picture is not uniform.
Does RAD140 cause aggression or anger?
Aggression and anger are linked to RAD140 among the effects described outside the trials, and they take the four forms listed below.
a short temper
irritability
anger hard to control
strain in close personal relationships, in a few accounts
RAD140 has also been described as causing no anger at all in other accounts, and as bringing a lifted mood and a rush of energy in a few. Its effects on mood therefore divide rather than run one way.
Does RAD140 cause anxiety?
Accounts outside the published studies describe anxiety as an effect of RAD140, seen as new restlessness and worry, and in a few accounts as a first panic attack, sometimes with palpitations. In descriptions beyond the trials, that anxiety sometimes ends exposure early, including where RAD140 was combined with MK-677. An absence of any change in anxiety has also been described, so the picture divides between new unease and an unaltered state.
Does RAD140 cause lethargy or tiredness?
Outside the trials, lethargy and tiredness are described as fatigue and a loss of motivation that arise more often in the middle weeks of exposure than at the start. The same pattern has also been described as recurring across more than one period of exposure in a few accounts. Greater energy is described, outside the trial record, in other accounts, so the picture of RAD140 and energy is not one-sided.
Does RAD140 cause headaches?
Headaches are among the most common early complaints and are described beyond the trial data as an effect RAD140 is able to cause. They often begin within the first days, are sometimes brought on by physical exertion and ease towards the end of each day. Such headaches have also been described as usually fading after the first week, and accounts outside the published studies describe headache, in some instances, as the only effect of RAD140 at all.
Does RAD140 cause back pain?
RAD140 has also been described as able to cause back pain during exposure, most often in the lower back and with a tightness there. In descriptions beyond the trials, cramping in skeletal muscle appears alongside the back pain, as does soreness in the shins in a few accounts. Outside the published trials such pain is described less often than the headaches above, and the descriptions leave open whether it is related to RAD140 at all.
Stomach, nose, skin and other complaints described in discussions
Flu-like symptoms and a sore throat appear early in exposure to RAD140 among the effects described outside the trials. Abdominal pain is described, outside the trial record, together with bloating, nausea and vomiting, diarrhoea and acid reflux, at times from the first days of exposure. Beyond the trial data, nosebleeds, itching of the skin and blurred vision are each described in a few accounts. Accounts outside the published studies describe most of these complaints only rarely, each in a handful of instances.
Do side effects depend on dose or cycle length?
Side effects appear across a wide range of RAD140 doses and cycle lengths, but for healthy humans no study among this article’s sources sets out a dose-response relationship, the way an effect changes with dose. The phase 1 trial tested 50, 100 and 150 mg once daily within that range and set the maximum tolerated dose at 100 mg, yet the later abstract recorded raised liver function tests at 10 mg twice daily, a far lower amount per day.
Time to onset in the case reports spread just as widely: myopericarditis in the 16-year-old boy followed first exposure, whereas drug-induced liver injury arose after 5 weeks, 3 months and 16 weeks. Gynaecomastia in the mixed-supplement case lies at the far end of that range, after 6 months of exposure to products holding several compounds. In keeping with that spread, one report classes the drug-induced liver injury it describes as idiosyncratic, a reaction not tied in a simple way to dose. On the published record, neither dose nor length of exposure predicts which harm appears or when, although a handful of cases cannot rule such a relation out.
Novel selective androgen receptor modulators such as RAD140 may be associated with idiosyncratic drug-induced liver injury.
Side effects of RAD140 in the first week of exposure are described only beyond the trial data, and headaches are the commonest of them. Each of the complaints below appears in accounts outside the published trials, in that same early period.
headaches, which often ease as that week goes on
a sudden nosebleed
shortness of breath with pressure across the chest or palpitations
flu-like symptoms with a sore throat
a sore lump beneath one nipple
early hair shedding
Accounts outside the published studies also describe a first week of exposure with no effect at all.
What happens after stopping
The harm reversed in most of the published cases after exposure to RAD140 stopped, although recovery took weeks to months, and in the most severe case the drug-induced liver injury at first kept progressing. The symptoms and liver injury of the 24-year-old man in the first case resolved after cessation; the 26-year-old man’s liver function panel was normal at the scheduled 2-month follow-up after discharge; the 29-year-old man’s symptoms resolved in the same way. Recovery was slowest in the 22-year-old man: his bilirubin had fallen from its peak to 188 µmol/L at one month, and his liver enzymes normalised 3 to 12 months after the product was discontinued.
[Figure 3. Bilirubin course in one RAD140 liver case. Total and direct bilirubin, in mg/dL, over 35 days in one 22-year-old man with liver injury after 16 weeks of RAD-140. Both rose for about two weeks, then fell, but both were still raised at day 35. One patient, not a typical course.]
That slow course fits a wider observation: another report notes that cholestasis can take weeks to months to clear and describes a prolonged case that resolved with corticosteroids. In the most severe case, by contrast, the drug-induced liver injury kept progressing despite cessation and corticosteroids. Effects outside liver tissue also cleared after cessation, among them the gynaecomastia and hypogonadotropic hypogonadism of the mixed-supplement case. Reversal is therefore the usual course in the published cases, though not a guaranteed one.
Do side effects like hair loss go away after stopping?
Outside the published trials, side effects of RAD140 such as hair shedding are described as easing some weeks after exposure ended, although other accounts leave open whether the hair loss is permanent. Accounts outside the published studies describe skin lesions and abdominal pain as beginning, or continuing, after exposure ended, and low mood and low energy have been described as arising in the weeks that follow, so the period after exposure carries its own set of complaints.
Why effects are hard to pin on RAD140 alone
Effects linked to RAD140 are hard to attribute to the compound alone, because several of the published cases involved other compounds or hidden hormones. The products in the gynaecomastia case combined RAD140, MK-677 and cardarine with undisclosed ingredients, compounds present in a product but missing from its label, among them testosterone, oestradiol and growth hormone. Andarine accompanied RAD140 in the most severe case of drug-induced liver injury, and MK-677 accompanied it in the case of splenic rupture, at an amount the report does not state against the studied MK-677 dosage.
Commercially available performance-enhancing supplements can contain banned performance-enhancing drugs (PEDs) and undisclosed steroid hormones that can induce hormonal abnormalities with associated clinical signs.
Such mixtures mean that an effect described in connection with RAD140 may come from another compound or from a hidden hormone, whether testosterone or one of the anabolic-androgenic steroids, the synthetic derivatives of testosterone, rather than from the SARM itself; the same caveat applies to what is described of RAD140, libido and erections.
A SARM certificate of analysis, by contrast, documents the composition of a reference sample: it is the laboratory record of a batch’s identity and purity, and it shows what a tested batch contained. Batch and purity data of that kind accompany the RAD-140 for sale on this site and the rest of the range, where laboratories buy UK SARMs for research, although a certificate documents identity and purity, not safety.
What studies in mice and rats found
In female mice, RAD140 at 5 mg/kg for 10 weeks raised mortality risk and the frailty index, a tally of age-related health deficits, above those of controls; it also lowered adaptive potential in young mice and did not improve their strength. The preclinical work, research in animals or cells before human testing, also includes rats. There RAD140 left bone structure unchanged in males over 14 days, and the triceps surae muscle weight after functional overload with RAD140 did not differ statistically from that after overload alone; in another rat study it largely spared prostate tissue. Animal results do not transfer directly to humans, so these findings frame questions for human studies rather than answer them.
Is RAD140 an approved medicine?
No SARM has received full clinical approval, and the WADA ban covers the class at all times, in and out of competition.
Where the evidence on RAD140 runs out
The evidence on the harms of RAD140 runs out quickly, because it rests on a single phase 1 trial in a small group of seriously ill women, the only full human study, and on later data that exist only as an abstract. Case reports form the second tier: they describe single patients and so cannot give a rate of harm in any population. In line with that gap, one case report calls the long-term effects and risks of SARMs unclear, and another describes the data on the adverse effects of RAD140 as very limited.
Several side effects of RAD 140 in this article rest only on descriptions outside the published trials, among them hair loss and shedding, acne and skin lesions, insomnia, night sweats and nightmares, anger, anxiety and panic attacks, and fatigue and lost motivation. The same holds for headaches, low back pain and skeletal muscle cramping, raised blood pressure, chest tightness, palpitations and shortness of breath, nipple swelling and lumps, and flu-like symptoms and sore throat. Such descriptions are the sole source for abdominal pain, bloating, nausea, diarrhoea, acid reflux, nosebleeds, itchy skin, blurred vision, and low mood and energy after exposure ended, and no published study among this article’s sources has measured any of them.
[Figure 4. RAD140’s human record since 2022. Human publications on RAD140 among this article’s sources, by year. One phase 1 trial and one phase 1/2 abstract, both in women with breast cancer, stand against case reports that each describe a single patient and so give no rate of harm.]
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
Which adverse events were most frequent in the only full human trial of RAD140?
Raised liver enzymes, AST and ALT ✓
Hair shedding and a receding hairline
Raised blood pressure and chest pain
Insomnia and sleep disturbances
In the phase 1 trial in women with advanced breast cancer, raised AST and ALT were the two commonest events; hair loss, blood pressure and insomnia appear only in accounts outside the trials.
In the published liver injury cases, what usually followed once exposure to RAD140 ended?
Most recovered, over weeks to months ✓
Liver tests settled within a few days
Most went on to lasting cirrhosis
Recovery needed steroid treatment first
Most of the men recovered after exposure ended, but slowly: in one case liver enzymes took 3 to 12 months to return to normal.
What complicates the one documented case of gynaecomastia linked to RAD140?
The products also held undeclared oestradiol ✓
RAD140 was being converted into oestrogen
He had gynaecomastia earlier in his life
His oestrogen levels had dropped far too low
Laboratory analysis found undeclared testosterone, oestradiol and growth hormone in his supplements alongside RAD-140, so the breast enlargement cannot be pinned on the SARM alone.
Which cardiac harm do published case reports describe after RAD140 exposure?
Inflammation of the heart muscle and its sac ✓
A heart attack from blocked coronary arteries
Thickening of the main pumping chamber
Very high blood pressure in trial patients
A 16-year-old boy developed myopericarditis, inflammation of the heart muscle and the sac around it, after his first exposure to a product sold as testolone.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
RAD 140 side effects: what the trials and case reports show
By Ailsa Gemmell · Reviewed by Elizabeth Hyams
Published · Updated · 23 min read
RAD140 side effects at a glance
Among RAD 140 side effects, the best documented is drug-induced liver injury, harm to liver tissue from a compound. RAD140 itself is an investigational compound from breast cancer research. Raised liver function tests were the commonest adverse events in the only full human trial, in women with advanced breast cancer, and published cases describe young men with jaundice.
In those cases drug-induced liver injury followed weeks to months of exposure, and most of the men recovered once exposure ended. Further case reports describe inflammation of cardiac tissue, whereas hair loss, acne, insomnia and mood changes are described only outside any trial.
RAD140 is a non-steroidal compound with tissue-selective androgenic activity, known as a selective androgen receptor modulator (SARM). The RAD 140 mechanism of action resembles that of androgens: it acts through a protein inside cells called the androgen receptor. Later trials tested RAD-140 under the development name vosilasarm, and case reports also call it testolone, the name on the product in one case of cardiac inflammation.
The evidence comes in three tiers. The first is the single full human trial, joined by a later abstract that recorded the same rises in liver function tests at a lower dose. The second is the case reports, which describe drug-induced liver injury, inflammation of cardiac tissue, and gynaecomastia, an enlargement of glandular breast tissue in males, with suppressed sex hormone levels after products that also held undeclared hormones. The third is the effects described outside any trial, drawn from RAD 140 experience reports on Reddit and in similar accounts.
Whether RAD 140 is safe or dangerous cannot be read from this record. Its documented harms are real, but they rest on a small trial and single cases, which give neither a safe dose nor a rate of harm in healthy adults. This article sets out what each tier records and leaves aside effects on skeletal muscle and legal detail beyond approval and sport.
What side effects did the human clinical trial report, and how often?
Raised liver function tests were the most frequent adverse events in the first-in-human phase 1 trial, an early safety test in humans. The two commonest were rises in the enzymes aspartate aminotransferase (AST), which injured liver cells release, and alanine aminotransferase (ALT), which is more liver-specific. The patients were heavily pretreated postmenopausal women with metastatic breast cancer positive for the oestrogen receptor, the protein in cells that responds to oestrogens. They received one of three once-daily doses; the severity table below gives the sizes and the arm numbers.
The chart shows these events, which count as treatment-emergent adverse events because they began or worsened during treatment. Among them is raised total bilirubin, a yellow pigment that liver cells clear into bile.
The investigators scored the events by adverse event grade, the standard scale of clinical severity on which a severe event is 3 and a life-threatening one 4. Events of grade 3 or 4 affected most patients, among them raised AST or ALT and hypophosphataemia, an abnormally low level of phosphate in the blood. Events related to treatment were slightly more common still, and the table below sets out their severity.
The trial set the maximum tolerated dose, the highest dose without unacceptable toxicity, at the middle of the three daily doses in the table. The elimination half-life, the time the blood concentration takes to halve, was 44.7 hours, which supported once-daily administration. On these data the authors judged the safety profile acceptable for patients with this cancer. Even so, a later phase 1/2 abstract of vosilasarm in the same disease recorded raised liver function tests at 10 mg twice daily. Together these figures make up most of the safety data from the RAD-140 clinical trials, and they come from a small group of older, ill and heavily pretreated patients, so the rates do not transfer neatly to healthy young men.
Was RAD140 linked to cancer in these studies?
RAD140 was not found to cause cancer in these studies, which tested it as a candidate treatment for breast tumours positive for both the androgen receptor and the oestrogen receptor (AR+/ER+). It activated the androgen receptor and slowed tumour growth in patient-derived xenografts, human tumours grown in laboratory mice, and it suppressed the oestrogen receptor pathway, including ESR1, the gene that encodes the oestrogen receptor. That activity showed tissue selectivity, a dependence on where the receptor sits: RAD140 activated it in breast cancer cells but not in prostate cancer cells, and in rats it largely spared the prostate.
In the trial itself, prostate-specific antigen (PSA), a protein produced in response to androgens, rose in 16 of 20 women, and the authors read the rise as a sign that RAD140 had reached the androgen receptor. These studies tested the compound against cancer in patients and models; none of them measured whether RAD 140 causes cancer in healthy humans.
Liver injury in the case reports
Case reports on RAD 140 and the liver describe drug-induced liver injury in young men after weeks to months of exposure to products labelled as supplements, and in each the injury was marked by cholestasis, an impairment of bile flow from the liver. The first report, set out with the others in the liver article, describes a young man who presented after some weeks of exposure with abdominal pain, itching, yellowing of the eyes and jaundice, a yellow discolouration caused by retained bilirubin. His injury was cholestatic, with a steep rise in total bilirubin, and a liver biopsy, a needle sample of liver tissue, showed cholestasis with minimal portal inflammation.
The published cases share a cholestatic pattern, which parallels the raised liver function tests of the phase 1 trial, as one of the reports itself points out. Other SARMs have been associated with the same pattern, so cholestasis is one of the liver effects of SARMs across the class, not of RAD140 alone.
Is RAD140 bad for the kidneys?
The evidence on RAD140 kidney effects amounts to acute kidney injury, a sudden fall in renal function, in a single published case of severe drug-induced liver injury after exposure to two compounds. That case cannot show whether RAD140 itself damages the organ.
It is the most severe drug-induced liver injury associated with RAD140 reported to date, in a previously healthy young man exposed to a supplement containing RAD140 and andarine (S4), an earlier SARM of the same class. His cholestatic injury kept progressing despite withdrawal of the supplement and treatment with corticosteroids, the steroid medicines that suppress inflammation, so he required plasmapheresis, a procedure that removes and replaces the liquid part of the blood. Pancreatitis, inflammation of the pancreas, and acute kidney injury then complicated his course further, and he required intensive care.
Heart inflammation and other serious case reports
Beyond drug-induced liver injury, case reports on RAD-140 and the heart describe inflammation of cardiac tissue, and one further report describes a splenic rupture, a tear of the spleen without preceding trauma. In the first heart case, a 16-year-old boy developed myopericarditis, inflammation of the heart muscle and the sac around it, after first exposure to a product sold as testolone; the authors call such adverse effects potentially life-threatening and poorly characterised. A separate case describes a young man who presented with possible acute myocarditis, inflammation confined to the cardiac muscle itself, after exposure to RAD140.
The splenic rupture occurred spontaneously in a 54-year-old man after recent exposure to RAD140 with MK-677 (ibutamoren), a compound that stimulates the release of growth hormone. The clinicians first blocked the bleeding splenic artery by embolisation and then removed the spleen. The removed tissue, however, showed features of a possible vascular malformation, and the authors call any role of the compounds speculative. That single case is the whole published record on RAD140 combined with MK-677, whose own record is set out under MK-677 side effects. None of these reports proves that RAD140 caused the harm, because each describes one patient.
Does RAD140 raise blood pressure or cause chest tightness?
Raised blood pressure and chest tightness are described beyond the trial data as effects RAD140 is able to cause, and in some accounts the tightness is severe enough to end exposure within the first weeks. Chest pain has also been described as an effect of RAD140, sometimes within the first days of exposure, alongside a faster heart rate, shortness of breath and palpitations, an awareness of a forceful or irregular heartbeat. Very high blood pressure is described, outside the trial record, as an occasional finding, now and then at levels regarded as dangerous. Accounts outside the published studies also describe the opposite: an uneventful course, free of any chest or cardiac symptom.
Does RAD140 cause gyno?
Only one documented case links RAD140 to gynaecomastia, an enlargement of glandular breast tissue in males, and the products in that case also held undisclosed hormones, so the enlargement cannot be attributed to RAD140 alone. That case report describes a 40-year-old man who developed bilateral gynaecomastia after 6 months of exposure to commercial supplements, together with hypogonadotropic hypogonadism, a state in which deficient pituitary or hypothalamic signalling leaves gonadal hormone output low, the same suppression that lies behind questions of RAD140 and testicle size. Laboratory analysis of those supplements found RAD-140, MK-677 and cardarine, a compound classed as performance-enhancing, together with undeclared growth hormone and two undeclared sex hormones: testosterone and oestradiol, the most potent natural oestrogen. The gynaecomastia resolved fully once exposure to the supplements ended.
Beyond that single case, the laboratory work on breast cancer offers only indirect context: in breast cancer models RAD140 activated the androgen receptor and suppressed the oestrogen receptor pathway. That work used cancer tissue in the laboratory rather than male breast tissue, so it does not show how RAD140 acts on the tissue that enlarges in gynaecomastia.
Nipple swelling and lumps described in discussions
In descriptions beyond the trials, swelling around the nipple or a small, tender lump beneath one nipple appears within the first weeks of exposure to RAD140, and in a few accounts within the first week itself. Gynaecomastia earlier in life is described, outside the trial record, as grounds for concern that the condition may recur. Accounts outside the published studies also set two further views side by side: that gynaecomastia cannot arise because RAD140 is not converted into oestrogen, and that levels of the hormone had fallen too low.
Testosterone, SHBG and other hormone changes
The sources record two hormone changes: a fall in a hormone-binding protein in the first-in-human trial, and suppressed testosterone production in one case. Sex hormone-binding globulin (SHBG), the protein that carries sex hormones in the blood, fell in all 18 women measured, and the authors took that fall as a marker of RAD140 acting on the androgen receptor. In men, testosterone production is governed by the hypothalamic-pituitary-gonadal axis, a feedback loop linking the hypothalamus, the pituitary gland and the gonads. The loop acts through luteinising hormone, the pituitary signal that drives testosterone production.
The RAD-140 hypogonadism case report records suppression of that axis: luteinising hormone and testosterone were both low, and they returned to normal together after exposure to the products ended. The products held undeclared testosterone and oestradiol as well as RAD-140, so the suppression cannot be attributed to the SARM alone, and the case cannot answer the question that remains when RAD140 acts by itself: does RAD 140 increase testosterone or lower it?
Does RAD140 cause hair loss?
In accounts outside the trials, RAD140 hair loss is the most widely described effect, in the form of shedding, thinning and a receding hairline. Such shedding begins, in those accounts, within the first days or weeks of exposure, most often where a predisposition to androgenetic alopecia, male-pattern baldness, already existed. Outside the published trials, exposure is sometimes said to have ended early because of that shedding, and RAD140 is widely described as acting strongly on scalp hair. In descriptions beyond the trials, however, an absence of any hair loss also appears.
Does RAD140 cause hair loss, and does it stop after the cycle?
RAD140 is described, outside the trial record, as causing hair shedding that starts a few weeks into exposure, eases and then stops some weeks later, whether the product was still being taken or not. The shedding has also been described as continuing after exposure ended, a course that leaves open when it stops and whether the loss is permanent. In descriptions beyond the trials, by contrast, no later shedding appears where none was seen at the start.
Does RAD140 cause acne?
Acne is described outside the trials as a possible effect of RAD140, seen as new lesions on the face and back and, in a few accounts, as red lesions on the back after exposure ended. In other instances accounts outside the published studies describe the skin as unchanged, and outside the published trials existing acne is described as clearing during exposure in a few accounts. The overall picture is mixed rather than pointing one way.
Does RAD140 cause insomnia?
Insomnia, widely set out as difficulty falling or staying asleep, early waking and a persistent shortage of rest, is described beyond the trial data as an effect RAD140 is able to cause. Accounts outside the published studies describe that disturbed sleep as accompanied by night sweats, a sensation of heat at night and nightmares. Outside the published trials, the time of day of exposure is sometimes described as a possible influence, a possibility that rests on description alone. Normal nights have also been described in other accounts, so the picture is not uniform.
Does RAD140 cause aggression or anger?
Aggression and anger are linked to RAD140 among the effects described outside the trials, and they take the four forms listed below.
RAD140 has also been described as causing no anger at all in other accounts, and as bringing a lifted mood and a rush of energy in a few. Its effects on mood therefore divide rather than run one way.
Does RAD140 cause anxiety?
Accounts outside the published studies describe anxiety as an effect of RAD140, seen as new restlessness and worry, and in a few accounts as a first panic attack, sometimes with palpitations. In descriptions beyond the trials, that anxiety sometimes ends exposure early, including where RAD140 was combined with MK-677. An absence of any change in anxiety has also been described, so the picture divides between new unease and an unaltered state.
Does RAD140 cause lethargy or tiredness?
Outside the trials, lethargy and tiredness are described as fatigue and a loss of motivation that arise more often in the middle weeks of exposure than at the start. The same pattern has also been described as recurring across more than one period of exposure in a few accounts. Greater energy is described, outside the trial record, in other accounts, so the picture of RAD140 and energy is not one-sided.
Does RAD140 cause headaches?
Headaches are among the most common early complaints and are described beyond the trial data as an effect RAD140 is able to cause. They often begin within the first days, are sometimes brought on by physical exertion and ease towards the end of each day. Such headaches have also been described as usually fading after the first week, and accounts outside the published studies describe headache, in some instances, as the only effect of RAD140 at all.
Does RAD140 cause back pain?
RAD140 has also been described as able to cause back pain during exposure, most often in the lower back and with a tightness there. In descriptions beyond the trials, cramping in skeletal muscle appears alongside the back pain, as does soreness in the shins in a few accounts. Outside the published trials such pain is described less often than the headaches above, and the descriptions leave open whether it is related to RAD140 at all.
Stomach, nose, skin and other complaints described in discussions
Flu-like symptoms and a sore throat appear early in exposure to RAD140 among the effects described outside the trials. Abdominal pain is described, outside the trial record, together with bloating, nausea and vomiting, diarrhoea and acid reflux, at times from the first days of exposure. Beyond the trial data, nosebleeds, itching of the skin and blurred vision are each described in a few accounts. Accounts outside the published studies describe most of these complaints only rarely, each in a handful of instances.
Do side effects depend on dose or cycle length?
Side effects appear across a wide range of RAD140 doses and cycle lengths, but for healthy humans no study among this article’s sources sets out a dose-response relationship, the way an effect changes with dose. The phase 1 trial tested 50, 100 and 150 mg once daily within that range and set the maximum tolerated dose at 100 mg, yet the later abstract recorded raised liver function tests at 10 mg twice daily, a far lower amount per day.
Time to onset in the case reports spread just as widely: myopericarditis in the 16-year-old boy followed first exposure, whereas drug-induced liver injury arose after 5 weeks, 3 months and 16 weeks. Gynaecomastia in the mixed-supplement case lies at the far end of that range, after 6 months of exposure to products holding several compounds. In keeping with that spread, one report classes the drug-induced liver injury it describes as idiosyncratic, a reaction not tied in a simple way to dose. On the published record, neither dose nor length of exposure predicts which harm appears or when, although a handful of cases cannot rule such a relation out.
Which side effects show up in the first week?
Side effects of RAD140 in the first week of exposure are described only beyond the trial data, and headaches are the commonest of them. Each of the complaints below appears in accounts outside the published trials, in that same early period.
Accounts outside the published studies also describe a first week of exposure with no effect at all.
What happens after stopping
The harm reversed in most of the published cases after exposure to RAD140 stopped, although recovery took weeks to months, and in the most severe case the drug-induced liver injury at first kept progressing. The symptoms and liver injury of the 24-year-old man in the first case resolved after cessation; the 26-year-old man’s liver function panel was normal at the scheduled 2-month follow-up after discharge; the 29-year-old man’s symptoms resolved in the same way. Recovery was slowest in the 22-year-old man: his bilirubin had fallen from its peak to 188 µmol/L at one month, and his liver enzymes normalised 3 to 12 months after the product was discontinued.
That slow course fits a wider observation: another report notes that cholestasis can take weeks to months to clear and describes a prolonged case that resolved with corticosteroids. In the most severe case, by contrast, the drug-induced liver injury kept progressing despite cessation and corticosteroids. Effects outside liver tissue also cleared after cessation, among them the gynaecomastia and hypogonadotropic hypogonadism of the mixed-supplement case. Reversal is therefore the usual course in the published cases, though not a guaranteed one.
Do side effects like hair loss go away after stopping?
Outside the published trials, side effects of RAD140 such as hair shedding are described as easing some weeks after exposure ended, although other accounts leave open whether the hair loss is permanent. Accounts outside the published studies describe skin lesions and abdominal pain as beginning, or continuing, after exposure ended, and low mood and low energy have been described as arising in the weeks that follow, so the period after exposure carries its own set of complaints.
Why effects are hard to pin on RAD140 alone
Effects linked to RAD140 are hard to attribute to the compound alone, because several of the published cases involved other compounds or hidden hormones. The products in the gynaecomastia case combined RAD140, MK-677 and cardarine with undisclosed ingredients, compounds present in a product but missing from its label, among them testosterone, oestradiol and growth hormone. Andarine accompanied RAD140 in the most severe case of drug-induced liver injury, and MK-677 accompanied it in the case of splenic rupture, at an amount the report does not state against the studied MK-677 dosage.
Such mixtures mean that an effect described in connection with RAD140 may come from another compound or from a hidden hormone, whether testosterone or one of the anabolic-androgenic steroids, the synthetic derivatives of testosterone, rather than from the SARM itself; the same caveat applies to what is described of RAD140, libido and erections.
A SARM certificate of analysis, by contrast, documents the composition of a reference sample: it is the laboratory record of a batch’s identity and purity, and it shows what a tested batch contained. Batch and purity data of that kind accompany the RAD-140 for sale on this site and the rest of the range, where laboratories buy UK SARMs for research, although a certificate documents identity and purity, not safety.
What studies in mice and rats found
In female mice, RAD140 at 5 mg/kg for 10 weeks raised mortality risk and the frailty index, a tally of age-related health deficits, above those of controls; it also lowered adaptive potential in young mice and did not improve their strength. The preclinical work, research in animals or cells before human testing, also includes rats. There RAD140 left bone structure unchanged in males over 14 days, and the triceps surae muscle weight after functional overload with RAD140 did not differ statistically from that after overload alone; in another rat study it largely spared prostate tissue. Animal results do not transfer directly to humans, so these findings frame questions for human studies rather than answer them.
Is RAD140 an approved medicine?
No SARM has received full clinical approval, and the WADA ban covers the class at all times, in and out of competition.
Where the evidence on RAD140 runs out
The evidence on the harms of RAD140 runs out quickly, because it rests on a single phase 1 trial in a small group of seriously ill women, the only full human study, and on later data that exist only as an abstract. Case reports form the second tier: they describe single patients and so cannot give a rate of harm in any population. In line with that gap, one case report calls the long-term effects and risks of SARMs unclear, and another describes the data on the adverse effects of RAD140 as very limited.
Several side effects of RAD 140 in this article rest only on descriptions outside the published trials, among them hair loss and shedding, acne and skin lesions, insomnia, night sweats and nightmares, anger, anxiety and panic attacks, and fatigue and lost motivation. The same holds for headaches, low back pain and skeletal muscle cramping, raised blood pressure, chest tightness, palpitations and shortness of breath, nipple swelling and lumps, and flu-like symptoms and sore throat. Such descriptions are the sole source for abdominal pain, bloating, nausea, diarrhoea, acid reflux, nosebleeds, itchy skin, blurred vision, and low mood and energy after exposure ended, and no published study among this article’s sources has measured any of them.
Check what you remember
4 questions on this article; the right answer is marked.
In the phase 1 trial in women with advanced breast cancer, raised AST and ALT were the two commonest events; hair loss, blood pressure and insomnia appear only in accounts outside the trials.
Most of the men recovered after exposure ended, but slowly: in one case liver enzymes took 3 to 12 months to return to normal.
Laboratory analysis found undeclared testosterone, oestradiol and growth hormone in his supplements alongside RAD-140, so the breast enlargement cannot be pinned on the SARM alone.
A 16-year-old boy developed myopericarditis, inflammation of the heart muscle and the sac around it, after his first exposure to a product sold as testolone.
Ailsa Gemmell · NHS Greater Glasgow and Clyde
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
Is MK-677 liver toxic? The liver and kidney evidence
Is MK-677 liver toxic: trials found it well tolerated, but a case report links it alone to raised liver enzymes that settled once exposure ended.
Is RAD140 liver toxic? What trials and case reports show
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
RAD 140 lethargy: mood, sleep and what the evidence shows
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
RAD 140 teenager: what a case report and animal data show
RAD 140 teenager evidence records harm: myopericarditis in a 16-year-old boy after his first dose, and raised frailty and mortality risk in mice.